Management of osteoarthritis and rheumatoid arthritis: Prospects and possibilities

American Journal of Medicine

Volumn 100, Issue 2 A, 1996, Pages 24S-30S

  Blackburn Jr , Warren D ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GOLD; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; PENICILLAMINE; PROSTAGLANDIN SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TISSUE TRANSPLANTATION; WEIGHT BEARING; DELAYED RELEASE FORMULATION; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DELAYED-ACTION PREPARATIONS; HUMANS; OSTEOARTHRITIS;

EID: 84928556979     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(97)89543-5     Document Type: Conference Paper

References (47)

1. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol. 1985;12:245-252.
2. Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum. 1987;30:507-512.
3. Makisara GL, Makisara P. Prognosis of functional capacity and work capacity in RA. Clin Rheumatol. 1982;1:117-125.
4. Pincus T, Callahan LF, Vaughn WK. Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol. 1987;14:240-251.
5. Proudfit WL, Bruschke AVG, Sones FM Jr. Natural history of obstructive coronary artery disease: ten-year study of 601 nonsurgical cases. Prog Cardiovasc Dis. 1978;21:53-78.
6. Kaplan HS. Survival as related to treatment. In: Kaplan HS, ed. Hodgkin's Disease. Cambridge, MA: Harvard University Press, 1972;3:360-388.
7. Mitchell DM, Spitz PW, Young DY, et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum. 1986;29:706-714.
8. Hess EV. Rheumatoid arthritis - treatment. In: Schumacher HR, ed. Primer on the Rheumatic Diseases, 9th ed. Richmond, VA: Wm Byrd Press, 1988:93-99.
9. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am. 1993;19:123-151.
10. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol. 1990;17(suppl 22):12-15.
11. Wilske KR, Healey LA. Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis. J Rheumatol. 1990;17(suppl 25):4-7.
12. Croggham JE, White PH. Challenging the pyramid: earlier, more aggressive treatment of RA. Drug Therapy. 1992;November:17-31.
13. Lipsky PE. Rheumatoid arthritis. In: Wilson JD, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine, 12th ed. New York: McGraw-Hill, 1991:1437-1443.
14. Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of Rheumatology, 4th ed. Vol 1. Philadelphia: W.B. Saunders, 1993.
15. van Schaardenburg D, Valkema R, Dijkmans BAC, et al. Prednisone treatment of elderly-onset rheumatoid arthritis. Arthritis Rheum. 1995;38:334-342.
16. Poole AR, Dieppe P. Biological markers in rheumatoid arthritis. Semin Arthritis Rheum. 1994;23(suppl 2):17-31.
17. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 1990;17:994-1002.
18. Flynn BL. Rheumatoid arthritis and osteoarthritis: current and future therapies. Am Pharm. 1994;NS34:31-42.
19. Physicians' Desk Reference, 49th ed. Montvale, NJ: Medical Economics Company, 1993:1519-1522,1596-1597,2397-2399.
20. Boyce E. Pharmacology of antiarthritic drugs. Clin Podiatr Med Surg. 1992;9:327-348.
21. Davis MJ, Dawes PT, Fowler PD, Clarke S, Fisher J, Shadforth MF. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol. 1991;30:451-454.
22. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum. 1994;37:1492-1498.
23. Williams HJ, Willkens RF, Samuelson CO Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1985;28:721-730.
24. Kremer JM, Alarcon GA, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 1994;37:316-328.
25. Carson CW, Cannon GW, Egger MJ, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rhem. 1987;16:186-195.
26. St Clair EW, Rice JR, Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med. 1985;145:2035-2038.
27. van Leeuwen MA, van Rijswijk MH, van der Heijde DMFM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol. 1993;32(suppl 3):9-13.
28. Dawes PT, Fowler PD, Clarke S, et al. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rhematol. 1986;25:4-49.
29. Larsen A. The relation of radiographic changes to acute-phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand J Rheumatol. 1988;17:123-129.
30. Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16:585-591.
31. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum. 1994;37:1487-1491.
32. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322:1277-1289.
33. Horneff G, Burmester GR, Emmrich F, Kalden JR. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum. 1991;30:459-463.
34. Wendling D, Wijdenes J, Racadot E, Morel-Fourrier B. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol. 1991;18:325-327.
35. Sipe JD, Bartle LM, Loose LD. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen: a possible correlate with clinical acute phase response. J Immunol. 1992;148:480-484.
36. Martel-Pelletier J, Ounissi H, Cloutier J-M, Pelletier J-P. Tenidap effectively reduces cytokine synthesis and expression by human rheumatoid arthritis synovium. (Abstr.) Arthritis Rheum. 1994;37(suppl):S-309.
37. 2 in vitro by mechanisms independent of inhibition of prostaglandin synthesis. Arthritis Rheum. 1991;34:192.
38. Dingle JT, Leeming MRG, Martindale JJ. Effect of tenidap on cartilage integrity in vitro. Ann Rheum Dis. 1993;52:292-299.
39. Littman BH, Drury CE, Schumacher R, Zimmerer R, Boyle D, Weisman M, Firestein G. In vivo reduction of RA synovial tissue metalloproteinase mRNA levels by tenidap. (Abstr.) Arthritis Rheum. 1994;37:S420.
40. Breedveld F. Tenidap: a novel cytokine-modulating antirheumatic drug for the treatment of rheumatoid arthritis. Scand J Rheumatol. 1994;23(suppl 100):31-44.
41. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425-434.
42. Kavanaugh A, Nichols L, Davis L, Rothlein R, Lipsky P. Anti-CD54 (ICAM-1) monoclonal antibody therapy in refractory RA. Arthritis Rheum. 1993;36:540.
43. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 1994;37:992-999.
44. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum. 1993;36:1681-1690.
45. Bradley JD, Brandt KD, Katz BP, Kalasmski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, and analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325:87-91.
46. Fernandes JC, Martel-Pelletier J, Otterness LG, et al. Effects of tenidap on canine experimental osteoarthritis (OA): I - Morphological analysis and metalloprotease activity. (Abstr.) Arthritis Rheum. 1994;37:S362.
47. Brittberg M, Lindahl A, Nilsson A, et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994;331:889-895.